Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | NT5E | P21589 | 1/20 | 0.60 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.59 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.54 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.54 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1389413 | 0.94 | ADORA3 (0.64) | DNPH1ADORA3TP53SLC29A1TDP1 | |
| SCHEMBL918126 | 0.92 | DNPH1 (0.58) | DNPH1ADORA3TP53SLC29A1TDP1 | |
| SCHEMBL918592 | 0.92 | DNPH1 (0.74) | DNPH1ADORA3TP53SLC29A1TDP1 | |
| SCHEMBL7971570 | 0.87 | ADORA3 (0.67) | DNPH1ADORA3TP53SLC29A1TDP1 | |
| SCHEMBL918835 | 0.86 | ADORA3 (0.59) | DNPH1ADORA3TP53SLC29A1TDP1 | |
| SCHEMBL24201476 | 0.85 | DNPH1 (0.65) | DNPH1ADORA3TP53SLC29A1TDP1 | |
| SCHEMBL7975005 | 0.85 | TYMP (0.55) | DNPH1ADORA3TP53SLC29A1TDP1 | |
| SCHEMBL10689750 | 0.84 | ADORA2A (0.59) | ADORA3P2RX3P2RX2 | |
| SCHEMBL6910225 | 0.82 | SLC29A1 (0.59) | DNPH1ADORA3TP53SLC29A1TDP1 | |
| SCHEMBL22983997 | 0.82 | P2RX3 (0.59) | DNPH1P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648188-B2 | Preparation of 2-chloro-9-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-adenine | SCINOPHARM TAIWAN, LTD. (TW) | 2014-02-11 | — | — | US | disclosed |
| US-20120010397-A1 | Preparation of 2-chloro-9-(2'-deoxy-2'-fluoro-Beta-D-arabinofuranosyl)-adenine | SCINOPHARM TAIWAN LTD. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010397-A1 | Preparation of 2-chloro-9-(2'-deoxy-2'-fluoro-Beta-D-arabinofuranosyl)-adenine | HPRT1, TYMP, MTAP | DNPH1 1793/4885ADORA3 71/4885TP53 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.